A CLIA (Clinical Laboratory Improvement Amendments) Waiver allows pharmacies to legally perform simple, low-risk diagnostic tests (CLIA-waived tests) onsite and report results. These tests provide immediate clinical insight and are reimbursed via medical claims.
A CLIA waiver allows pharmacies to generate billable clinical encounters through tests like A1c, INR, flu, COVID, and strep—maximizing the value of each patient interaction.
Over time, a consistent practice of CLIA-waived testing increases patient touchpoints, visit frequency and revenue per encounter. Testing services pair naturally with immunizations, DSME counseling, MTM, CCM, and RPM
To expand into clinical services and medical billing, a pharmacist must first obtain a Collaborative Practice Agreement. Here’s some guidance to do so:
Once approved, the pharmacy receives a CLIA Certificate of Waiver, allowing immediate testing once:
This step is critical to turning testing into revenue, not just clinical activity.
A CLIA waiver is one of the simplest, highest-ROI credentials a pharmacy can obtain. It enables medical billing, expands clinical services, and serves as a foundation for long-term growth in 2026 and beyond.
If you’re ready to implement testing the right way, a CLIA waiver is where it starts.